Kineta Inc (KA)

$0.72

-0.04

(-5.44%)

Market is closed - opens 7 PM, 15 Jul 2024

Performance

  • $0.71
    $0.76
    $0.72
    downward going graph

    1.39%

    Downside

    Day's Volatility :6.58%

    Upside

    5.26%

    downward going graph
  • $0.33
    $5.39
    $0.72
    downward going graph

    53.63%

    Downside

    52 Weeks Volatility :93.81%

    Upside

    86.64%

    downward going graph

Returns

PeriodKineta Inc
3 Months
112.06%
6 Months
-74.57%
1 Year
-69.71%
3 Years
-85.43%

Highlights

Market Capitalization
10.2M
Book Value
- $0.56
Earnings Per Share (EPS)
-1.4
Wall Street Target Price
13.5
Profit Margin
0.0%
Operating Margin TTM
-303.1%
Return On Assets TTM
-126.29%
Return On Equity TTM
-369.01%
Revenue TTM
5.2M
Revenue Per Share TTM
0.44
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
9.1M
EBITDA
-15.6M
Diluted Eps TTM
-1.4
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.41
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Kineta Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1775.0%

Current $0.72
Target $13.50

Technicals Summary

Sell

Neutral

Buy

Kineta Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Kineta Inc
Kineta Inc
53.4%
-74.57%
-69.71%
-85.43%
-85.43%
Moderna, Inc.
Moderna, Inc.
-16.37%
18.89%
-4.07%
-48.35%
748.18%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
7.16%
17.36%
52.58%
90.65%
268.9%
Novo Nordisk A/s
Novo Nordisk A/s
-0.29%
33.6%
81.13%
227.9%
496.35%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
2.03%
11.71%
40.03%
146.43%
177.11%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Kineta Inc
Kineta Inc
NA
NA
NA
-1.41
-3.69
-1.26
NA
-0.56
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.64
31.64
1.46
44.29
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.22
49.22
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.94
31.94
0.53
17.02
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Kineta Inc
Kineta Inc
Buy
$10.2M
-85.43%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$47.1B
748.18%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$118.0B
268.9%
31.64
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$635.7B
496.35%
49.22
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.9B
177.11%
31.94
39.46%

Company Information

proteostasis therapeutics is discovering and developing novel small molecule therapeutics designed to control the body’s protein homeostasis, or proteostasis network. the proteostasis network maintains the body’s natural balance of proteins to protect us from numerous diseases. these novel therapies, or proteostasis regulators, are designed to treat multiple genetic and degenerative disorders associated with deficiencies of the proteostasis network, such as alzheimer’s disease, emphysema, huntington’s disease, and type ii diabetes.

Organization
Kineta Inc
Employees
11
CEO
Mr. Craig W. Philips
Industry
Miscellaneous

FAQs